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Abstract
Background: Boron neutron capture therapy (BNCT) is an alternative treatment modality for patients with glioma.
The aim of this study was to determine whether induction of apoptosis contributes to the main therapeutic
efficacy of BNCT and to compare the relative biological effect (RBE) of BNCT, g-ray and reactor neutron irradiation.
Methods: The neutron beam was obtained from the Xi’an Pulsed Reactor (XAPR) and g-rays were obtained from
[
60Co] g source of the Fourth Military Medical University (FMMU) in China. Human glioma cells (the U87, U251, and
SHG44 cell lines) were irradiated by neutron beams at the XAPR or [
60Co] g-rays at the FMMU with different
protocols: Group A included control nonirradiated cells; Group B included cells treated with 4 Gy of [
60Co] g-rays;
Group C included cells treated with 8 Gy of [
60Co] g-rays; Group D included cells treated with 4 Gy BPA (p-borono-
phenylalanine)-BNCT; Group E included cells treated with 8 Gy BPA-BNCT; Group F included cells irradiated in the
reactor for the same treatment period as used for Group D; Group G included cells irradiated in the reactor for the
same treatment period as used for Group E; Group H included cells irradiated with 4 Gy in the reactor; and Group I
included cells irradiated with 8 Gy in the reactor. Cell survival was determined using the 3-(4,5-dimethylthiazol-2-yl-
2,5-diphenyltetrazolium (MTT) cytotoxicity assay. The morphology of cells was detected by Hoechst33342 staining
and transmission electron microscope (TEM). The apoptosis rate was detected by flow cytometer (FCM). The level
of Bcl-2 and Bax protein was measured by western blot analysis.
Results: Proliferation of U87, U251, and SHG44 cells was much more strongly inhibited by BPA-BNCT than by
irradiation with [
60Co] g-rays (P < 0.01). Nuclear condensation was determined using both a fluorescence technique
and electron microscopy in all cell lines treated with BPA-BNCT. Furthermore, the cellular apoptotic rates in Group
D and Group E treated with BPA-BNCT were significantly higher than those in Group B and Group C irradiated by
[
60Co] g-rays (P < 0.01). The clonogenicity of glioma cells was reduced by BPA-BNCT compared with cells treated in
the reactor (Group F, G, H, I), and with the control cells (P < 0.01). Upon BPA-BNCT treatment, the Bax level
increased in glioma cells, whereas Bcl-2 expression decreased.
Conclusions: Compared with g-ray and reactor neutron irradiation, a higher RBE can be achieved upon treatment
of glioma cells with BNCT. Glioma cell apoptosis induced by BNCT may be related to activation of Bax and
downregulation of Bcl-2.
Background
Glioma is one of the most aggressive human malignan-
cies. Despite aggressive surgery combined with adjuvant
radiotherapy and chemotherapy, patient prognosis
remains poor. It is thus essential to develop novel
therapeutic strategies to treat glioma. Boron neutron
capture therapy (BNCT) is a highly selective treatment
modality that can target the tumor without causing
excessive radiation damage to the normal tissues [1].
The ability of [
10B] to capture thermal neutrons, and to
then disintegrate immediately into a He nucleus (an a
particle) and a Li nucleus, is utilized in BNCT [2]. Both
the He and Li nuclei have high lineal energy transfer
(LET) values, with path-lengths approximately the dia-
meter of a single cell; the lethality of these nuclei is thus
* Correspondence: xzhang@fmmu.edu.cn
† Contributed equally
1Department of Neurosurgery of Xijing Hospital, Fourth Military Medical
University, Xi’an, Shaanxi 710032, P.R.China
Full list of author information is available at the end of the article
Wang et al. BMC Cancer 2010, 10:661
http://www.biomedcentral.com/1471-2407/10/661
© 2010 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.primarily limited to boron-containing cells [3]. BNCT
has been carried out in numerous studies using syn-
geneic rat gliomas [3-6]. Approaches such as administer-
ing [
10B] by intra-arterial injection with or without
blood-brain barrier (BBB) disruption [7-9], or intracer-
ebral delivery of high molecular weight agents by means
of convection enhanced delivery following neutron beam
irradiation [2,10], confirm that BNCT is highly effective
for treatment glioma xenograft models. In clinic, BNCT
has been used in various countries to treat patients with
high-grade glioma, melanoma, liver metastasis of colon
adenocarcioma, malignant melanomas, oral cancer, and
therapeutically refractory, recurrent tumors of the head
and neck [3,6,11-15]; while the mechanism of BNCT-
induced cell death remains unclear.
We treated U87, U251, and SHG44 glioma cells with
BNCT in vitro, using L-p-borono-phenylalanine (L-BPA)
as the boron carrier and the thermal neutron source of
the Xi’an Pulsed Reactor (XAPR) in China as the irra-
diator. The relative biological effect (RBE) of BNCT on
tested cells, especially with respect to apoptosis induc-
tion, was assessed, and a possible mechanism of BNCT
action was presented.
Methods
Glioma cell culture
The human glioblastoma multiforme cell lines U87 and
U251 were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). The human anaplas-
tic astrocytoma cell line SHG44 was purchased from the
Institute of Biochemistry and Cell Biology (IBCB; Shang-
hai, China). Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Grand Island, NY)
with 10% (v/v) fetal bovine serum (Gibco) and 0.5%
(w/v) penicillin-streptomycin solution (Gibco), at 37°C
under 5% CO2 and 95% air (both v/v).
Boron uptake by glioma cells in vitro
[
10B]-enriched L-BPA (Ryscor Inc., Raleigh, NC) was
used in the study. L-BPA was added to the culture
m e d i ao fg l i o m ac e l l st o5 0μg[
10B]/ml. Cells in the
exponential phase of growth were cultured in boron-
containing medium for 3, 6, 12, or 24 h before harvest-
ing, and boron concentrations were determined by
inductively coupled plasma atomic emission spectro-
scopy (ICP-AES) (VISTA-MP X ;V a r i a nC o . ,W a l n u t
Creek, CA) according to a previously described method
[16].
In vitro irradiation
In vitro irradiation of the three cell lines was performed
using the neutron beam at the XAPR whereas in vitro
g-ray irradiation by the [
60Co] g source was performed
in the Fourth Military Medical University (Xi’an, China).
Cells were divided into nine groups. Group A was con-
trol nonirradiated cells; Group B cells were irradiated
with 4 Gy of [
60Co] g-rays; Group C cells were irradiated
with 8 Gy of [
60Co] g-rays; Group D cells were irra-
diated with 4 Gy BPA-BNCT; Group E cells were irra-
diated with 8 Gy BPA-BNCT; Group F cells were
irradiated in the XAPR for the same treatment period as
used for Group D; Group G cells were irradiated in the
XAPR for the same treatment period as used for Group
E; Group H cells were irradiated with 4 Gy in the
XAPR; and Group I cells were irradiated with 8 Gy in
t h eX A P R .I nG r o u pDa n dG r o u pEw i t hB P A - B N C T ,
cells were incubated for 24 h in medium with BPA and
washed three times with phosphate-buffered saline
(PBS); the medium was next replaced with boron-free
medium; cells were exposed to the XAPR with irradia-
tion doses of 4 Gy and 8 Gy, respectively. In the g-ray-
treated Group B and Group C, cells incubated in growth
medium without BPA were exposed to the g-rays with
irradiation doses of 4 Gy and 8 Gy, respectively. In
Group F and Group G, cells incubated in medium with-
out BPA were exposed to the XAPR with identical treat-
ment durations of Group D and Group E, respectively.
In Group H and Group I, cells incubated in growth
medium without BPA were exposed to the XAPR with
i r r a d i a t i o nd o s e so f4G ya n d8G y ,r e s p e c t i v e l y .I r r a -
diated and nonirradiated cells were placed at room tem-
perature and under a normal atmosphere during
irradiation. At the beginning of the experiment, all cells
were in the exponential phase of growth and at a den-
sity of 3×10
5/ml. The components of the reactor neu-
tron source and the [
60Co] g source were shown in
Table 1; the irradiation periods of various groups were
listed in Table 2; the dose components of BNCT were
listed in Table 3 and Table 4. The irradiation doses
were calculated according to previous studies [17,18].
Proliferation assays
Cell survival was determined using the 3-(4,5-
dimethylthiazol-2-yl-2,5-diphenyltetrazolium (MTT)
(Sigma, St. Louis, MO) assay. After irradiation, cells
were trypsinized and washed, and cell concentrations
were adjusted to 10
4 cells/ml. Cells were seeded into the
Table 1 Dose rates for reactor neutron source and [60Co]
g source
Components Dose rate (Gy/min)
Dose rates for the reactor
neutron source
Thermal neutron 1.04×10
-3
Epithermal neutron 2.48×10
-4
Fast neutron 1.07×10
-1
g-ray 1.57×10
-2
10B(n,a)
7Li 5.09×10
-4/ppm
10B
Dose rate for the [
60Co] g source 1.40×10
1
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Page 2 of 9wells of 96-well microplates (Nunc, Roskilde, Denmark)
and incubated for 2, 4, or 6 days. The culture medium
was removed and replaced with 100 μla l i q u o t so ff r e s h
medium, without serum, containing 0.5 mg/ml MTT,
followed by 4 h of incubation at 37°C. Next, medium
was aspirated from the wells and 100 μl dimethyl sulfox-
ide (DMSO) was added to each well, to dissolve forma-
zan crystals. Optical density (OD) was measured using
an enzyme-linked immunosorbent method. Cell num-
bers were derived from OD values by reference to a
standard cell number-OD curve.
Hoechst staining
At 12 h, 24 h, 36 h, and 48 h after treatment with BPA-
BNCT, cells were fixed for 10 min in 4% (v/v) parafor-
maldehyde, and then incubated with Hoechst 33342 dye
(Sigma) (10 μg/ml) for 10 min. After washed with PBS,
cells were observed using an inverted fluorescence
microscope (IX70; Olympus, Tokyo, Japan).
Electron microscopy
Forty-eight hours after irradiation, cells were detached
from plates, washed, suspended in PBS, and concen-
trated by centrifugation. Cell samples were fixed in 2.5%
(v/v) glutaraldehyde in 0.1 M phosphate buffer (pH 7.4),
postfixed in 2% (w/v) buffered osmium tetroxide for 2 h,
and dehydrated in ethanol. Specimens for transmission
electron microscopy were embedded in Epon. Thin sec-
tions were cut using an ultramicrotome and double-
stained with uranyl acetate and lead citrate. Electron
micrography was performed (JEM-2000EX; JEOL,
Tokyo, Japan) using an operating voltage of 80 kV.
AnnexinV/PI analysis
Twelve hours, 24 h, 36 h, and 48 h after irradiation,
cells were trypsinized, counted, washed twice in ice-cold
PBS solution, and resuspended in 1×binding buffer (10
mM HEPES/NaOH [pH 7.4], 140 mM NaCl, and 2.5
mM CaCl2). Next, 5 μlo fa n n e x i nV - F I T C( A V )( R & D
Systems Europe Ltd., Abingdon, UK) and 10 μl of propi-
dium iodide (PI) (Sigma) were added to 100 μlo fc e l l
suspension, followed by incubation for 15 min at room
temperature in the dark. Finally, 400 μl of binding buffer
was added to each sample, which was held on ice prior
to analysis on a FACSCalibur (Becton Dickinson Lab-
ware, Franklin Lakes, NJ) flow cytometer. Ten thousand
cells per sample were analyzed.
Clonogenic assay
After irradiation, 200 treated cells were plated in six-
well flat-bottomed microplates (Nunc) and incubated at
37°C in a humidified incubator under 5% (v/v) CO2 for
2 weeks. The cells were fixed in methanol and stained
with Giemsa’s solution. Colonies ≥ 50 μm in diameter
were counted [19].
Western blot analysis
Twelve hours and 24 h after irradiation, cells were
washed twice in ice-cold PBS and protein extracts of
U87, U251, and SHG44 cells were prepared by lysis in
RIPA buffer (150 mM NaCl, 1% [v/v] NP-40, 0.5% [w/v]
sodium deoxycholate, 0.1% [w/v] sodium dodecyl sulfate
(SDS), 50 mM Tris HCl [pH 8], 10 mM EDTA, and 1
mM PMSF [Sigma]) for 30 min at 4°C. Samples were
next centrifuged for 15 min at 15,000 g. Protein concen-
trations of supernatants were determined. For each
sample, 60 μg of protein was loaded on a 12.5% (w/v)
SDS-polyacrylamide gel, electrophoresed, and trans-
ferred to a nitrocellulose membrane (Protran; Schleicher
and Schuell, Florham Park, NJ). Each membrane was
blocked for 1 h at room temperature with blocking buf-
fer (TBS containing 0.1% [v/v] Tween 20 [Sigma] and
5% [w/v] milk powder). Primary antibodies (applied for
1 h at room temperature, or overnight at 4°C) were:
anti-Bcl-2 (Santa Cruz Biotechnology, Inc., Heidelberg,
Germany), anti-Bax (Santa Cruz), and anti-actin (mouse
monoclonal C-2, Santa Cruz). Antibodies were diluted
1:1,000, except for the anti-actin antibody (1:500).
Table 2 The irradiation periods of various groups
Group A
(min)
Group B
(min)
Group C
(min)
Group D
(min)
Group E
(min)
Group F
(min)
Group G
(min)
Group H
(min)
Group I
(min)
U87 64 0.29 0.57 27 54 27 54 32 64
U251 64 0.29 0.57 25 50 25 50 32 64
SHG44 64 0.29 0.57 28 56 28 56 32 64
Table 3 The dose components of BNCT 4 Gy
Thermal neutron (Gy) Epithermal neutron (Gy) Fast neutron (Gy) g-ray (Gy)
10B(n,a)
7Li (Gy)
U87 0.028 0.007 2.889 0.423 0.653
U251 0.026 0.007 2.675 0.392 0.900
SHG44 0.029 0.007 2.996 0.439 0.529
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HRP-labeled secondary antibodies (Amersham Pharma-
cia Biotech, Uppsala, Sweden), either sheep anti-mouse
(diluted 1:2,500) or donkey anti-rabbit (1:5,000), and the
blots were finally developed using an ECL system,
according to the manufacturer’s instructions (Amersham
Bioscience, Buckinghamshire, UK).
Statistical analysis
Outcome variables are expressed as means ± standard
deviations (SDs). Statistical analysis was performed
using SPSS Version 13.0 (SPSS, Chicago, IL). ANOVA
was used for data analysis. All statistical tests were two-
sided, and P values < 0.05 were considered to be statisti-
cally significant.
Results
Boron uptake
As expected, [
10B] was taken up by U87, U251, and SHG44
cells during incubation for 24 hours in medium containing
50 μg[
10B]/ml. The boron concentrations in cells even-
tually reached 2.72 ± 0.25 μg/10
7 cells, 9.78 ± 0.49 μg/10
7
cells, and 2.48 ± 0.34 μg/10
7 cells for the U87, U251, and
SHG44 cell lines, respectively, at 24 h (Figure 1).
Tumor cell numbers fall after BPA-BNCT treatment
The inhibitory effect of BPA-BNCT on proliferation of
U87 cells was much more significant than that afforded
by g-rays, as confirmed by the MTT assay (P <0 . 0 1 ,
Figure 2). Any inhibitory effect was marginal in cells
receiving 4 Gy or 8 Gy of g-rays, whereas significant inhi-
bition was observed in cells treated with 4 Gy or 8 Gy of
BPA-BNCT. The number of viable U87 cells decreased in
48 h after treatment in all of Groups D, E, F, G, H, and I,
and the most potent inhibition was observed in the
group receiving 8 Gy of BPA-BNCT. Similar effects were
observed in SHG44 and U251 cells (data not shown).
BNCT induces apoptosis
Typical apoptotic morphological changes were found in
all of the U87, U251, and SHG44 cell lines 12 h after
treatment with BPA-BNCT;t h ec h a n g e si n c l u d e d
shrinkage, deformation, and detachment from culture
dishes. Nuclear condensation and chromatin margina-
tion were evident by Hoechst 33342 staining (Figure 3A,
3B), and chromatin margination, nuclear condensation,
and segmentation were noted on transmission electron
microscopy (Figure 3C).
The apoptotic frequency of U87 cells treated with 4 Gy
or 8 Gy of BPA-BNCT was significantly higher than that of
cells treated with equivalent doses of g-rays (P < 0.01), as
shown by annexin V/PI staining (Figure 4, 5). Furthermore,
the apoptotic frequency of cells treated with 8 Gy
Table 4 The dose components of BNCT 8 Gy
Thermal neutron (Gy) Epithermal neutron (Gy) Fast neutron (Gy) g-ray (Gy)
10B(n,a)
7Li (Gy)
U87 0.056 0.013 5.778 0.846 1.306
U251 0.052 0.013 5.350 0.748 1.800
SHG44 0.058 0.013 5.992 0.878 1.058
Figure 1 Time course of boron accumulation. Data represent the
mean ± SD of triplicate experiments.
Figure 2 Growth curves of U87 cells in different groups.G r o u p
A; control nonirradiated cells; Group B: cells treated with 4 Gy of
[
60Co] g-rays; Group C: cells treated with 8 Gy of [
60Co] g-rays; Group
D: cells treated with 4 Gy BPA-BNCT; Group E: cells treated with 8
Gy BPA-BNCT; Group F: cells irradiated in the reactor for the same
treatment period as used for Group D; Group G: cells irradiated in
the reactor for the same treatment period as used for Group E;
Group H: cells irradiated with 4 Gy in the reactor; Group I: cells
irradiated with 8 Gy in the reactor. Data represent the mean ± SD
of triplicate experiments.
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4 Gy BPA-BNCT (P < 0.01). Also, the apoptotic frequen-
cies of U87 cells after BPA-BNCT treatment were greater
than those noted after delivery of equivalent reactor doses
of irradiation (P < 0.05). Similar effects were observed in
SHG44 and U251 cells (Figure 4, 5).
BNCT inhibits colony formation
The survival rates of nonirradiated control cells were set at
100%. Cell survival proportions were shown in Table 5.
Survival analysis of U87, U251, and SHG44 cells showed
that all three cell lines were inhibited more potently by
BNCT than by irradiation with [
60Co] g-rays (P < 0.01) or
by general reactor neutron irradiation (P < 0.01).
Altered expression of Bcl-2 and Bax after BNCT
In all of U87, U251, and SHG44 cells, Bcl-2 was initially
abundantly expressed, whereas Bax expression was low.
After treatment with 4 Gy or 8 Gy of BPA-BNCT, Bcl-2
expression was down-regulated, while Bax expression
increased simultaneously. Furthermore, 24 h after treat-
ment with 4 Gy BPA-BNCT, Bcl-2 expression was lower
than that seen 12 h after treatment with 4 Gy BPA-
BNCT, and the level of Bax expression was higher. The
levels of Bcl-2 and Bax expression were similar 12 h and
24 h after treatment with 8 Gy BPA-BNCT (Figure 6).
Discussion
T w oc r i t e r i am u s tb ef u l f i l l e dw h e nB N C Ti st ob e
applied: an appropriate source of high-flux thermal neu-
trons is necessary, along with a boron carrier that is
Figure 3 Morphologic changes in glioma cells following BPA-
BNCT treatment. (A) Hoechst staining. White arrows indicate
apoptotic cells in U87 cells, U251 cells, and SHG44 cells, respectively.
Original magnification×400; bar: 10 μm. (B) Phase-contrast
microscopy. White arrows indicate apoptotic cells in U87 cells, U251
cells, and SHG44 cells, respectively. Original magnification×400; bar:
10 μm. (C) Transmission electron microscopy. Left, U87 cells;
original magnification×6,000; bar: 1 μm; middle, U251 cells; original
magnification×5,000; bar: 1 μm; right, SHG44 cells; original
magnification×6,000; bar: 1 μm.
Figure 4 Apoptosis of glioma cells induced by BPA-BNCT.( A )
U87 cells; a-1, nonirradiated control; a-2, 48 h after treatment with 4
Gy BPA-BNCT; a-3, 48 h after treatment with 8 Gy BPA-BNCT. (B)
SHG44 cells; b-1, nonirradiated control; b-2, 48 h after treatment
with 4 Gy BPA-BNCT; b-3, 48 h after treatment with 8 Gy BPA-BNCT.
(C) U251 cells; c-1, nonirradiated control. c-2, 48 h after treatment
with 4 Gy BPA-BNCT; c-3, 48 h after treatment with 8 Gy BPA-BNCT.
Figure 5 At 48 h after irradiation the apoptotic frequencies of
glioma cells in the nine groups. Group A; control nonirradiated
cells; Group B: cells treated with 4 Gy of [
60Co] g-rays; Group C: cells
treated with 8 Gy of [
60Co] g-rays; Group D: cells treated with 4 Gy
BPA-BNCT; Group E: cells treated with 8 Gy BPA-BNCT; Group F: cells
irradiated in the reactor for the same treatment period as used for
Group D; Group G: cells irradiated in the reactor for the same
treatment period as used for Group E; Group H: cells irradiated with
4 Gy in the reactor; Group I: cells irradiated with 8 Gy in the reactor.
Data represent the mean ± SD of triplicate experiments.
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initially verified uptake of BPA by glioma cells in vitro.
We found that the boron concentration in the three
glioma cell lines increased constantly over the first 24
hours of incubation. Irradiation was conducted at this
time, and the [
10B] level attained the theoretical require-
m e n t ,i nt h a ta tl e a s t1 0
9 [
10B] atoms accumulated in
each glioma cell and the thermal neutron fluence could
attain 10
12-10
13n·cm
-2, to produce a lethal discharge of
high-LET particles [20].
BNCT can inhibit cell proliferation because the RBE is
high, as has been shown in animal models. In the pre-
sent study, although the three glioma cell lines differed
in boron concentration after exposure to BPA, the ther-
apeutic efficiency of BNCT was similar in all three lines
because the RBE was high. Proliferation of glioma cells
was significantly suppressed by BNCT, and the clono-
genicity of glioma cells after BNCT treatment was less
than 0.01% of control values.
Apoptosis, an active process of cellular suicide, is an
important means of radiation-induced cell death [21],
and may contribute to the therapeutic efficacy of BNCT.
Many triggers of apoptosis are known, including cytoge-
netic alterations such as micronuclei (MN) formation
and chromosomal aberrations (CA) within cellular sys-
tems [22]. Furthermore, several studies have sought to
correlate the extent of apoptosis after irradiation with
cellular radiosensitivity [23]. Given that BNCT works
mainly through the discharge effects of high-LET Li
nuclei and a particles, we investigated whether BNCT
could induce apoptosis of glioma cells. Typical apoptotic
morphological changes were confirmed in U87, U251,
and SHG44 cells after BNCT treatment, using transmis-
sion electron microscopy and Hoechst 33342 staining.
Furthermore, previous studies have shown that BPA has
no toxicity effect on cells at a dosage up to 110 μg
[
10B]/ml [24]. Few apoptotic changes were apparent in
nonirradiated control cells, showing, for the first time,
that the pro-apoptotic effect of BNCT plays an impor-
tant role in the reduction of cell proliferation. Masunaga
et al. described that BNCT induced apoptosis in vivo,
the proportion of apoptotic cells increased slightly 6 h
after BNCT, and the apoptotic rate was relatively low
[17,18]. Fujita et al. stated that apoptosis was a form of
cell death induced by BNCT [25]. While Aromando et
al. reported that apoptosis did not have a significant role
in BNCT-induced hamster cheek pouch tumor control
[26], and Kamida et al. described that differences in
apoptotic cells pre- and post-BNCT in human oral
squamous cell carcinoma xenografts were minimal [27].
Whether BNCT can induce significant apoptosis rate in
glioma cells in vivo and whether the pro-apoptotic effect
is cell-type-dependant deserved further study.
It is well established in mammalian systems that high-
LET irradiations have more pronounced effects on bio-
logical systems than that of low LET [22], owing to the
characteristic mode of energy deposition along a track.
Such energy generates complex forms of radiation
damage to biological molecules. The transfer of the
energy of high-LET radiation to such molecules can
break chemical bonds and ionize various cellular
components.
In the present study, AnnexinV/PI analysis not only
confirmed the pro-apoptotic effect of BNCT, but also
showed that apoptosis frequencies were higher in groups
treated with BNCT compared with g-rays. Moreover, the
Table 5 Survival fractions of glioma cells in different groups
Group Survival fraction (%)
U87 U251 SHG44
Unirradiated control (A) 100 100 100
Irradiated in
60Co by 4 Gy (B) 68.1 63.7 64.5
Irradiated in
60Co by 8 Gy (C) 10.9 13.6 12.4
Irradiated in reactor for the same treatment period as used for Group D (F) 3.1 2.3 2.5
Irradiated in reactor for the same treatment period as used for Group E (G) 1.6 1.4 1.6
Irradiated in reactor by 4 Gy (H) 2.9 2.2 2.6
Irradiated in reactor by 8 Gy (I) 1.4 0.9 1.2
Irradiated in reactor with BNCT by 4 Gy (D)* <0.01% <0.01% <0.01%
Irradiated in reactor with BNCT by 8 Gy (E)** <0.01% <0.01% <0.01%
*P <0.01 vs A, B, F and H **P <0.01 vs A, C, G, I and D
Figure 6 The expression of Bcl-2 and Bax proteins in (A) U87
cells, (B) U251 cells, and (C) SHG44 cells, 12 h and 24 h after
treatment with 4 Gy or 8 Gy BPA-BNCT.
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than those of the irradiated controls. Additionally, when
the absorbed doses were identical, both the proliferation
and the clonogenicity of glioma cells were suppressed by
BNCT to an extent significantly greater than seen after
exposure to a neutron beam. Thus, the RBE of BNCT is
higher than that of either a neutron beam or g-rays.
In the present study, the contribution of a boron-
dependent dose to the total BNCT dose was low. Thus,
with optimization of the reactor and improvement in
the boron-dependent dose, the RBE of BNCT can be
further increased.
Previous studies have shown that the intrinsic apopto-
tic pathway (involving the mitochondria) plays a key
role in the regulation of apoptosis in response to irradia-
tion [28]. Bcl-2 family proteins interact to permeabilize
the mitochondrial membrane, thus playing an important
role in irradiation-induced apoptosis [29-31]. Bcl-2 and
Bax, the two main members of the Bcl-2 protein family,
function as tumor anti-apoptotic and pro-apoptotic fac-
tors, respectively [32-34]. Bax can cause release of cyto-
chrome c after formation of the hetero-oligomer Bax/
Bak, whereas Bcl-2 can engage with activator proteins
or Bax/Bak, thereby sequestering these proteins [28].
We detected expression of Bcl-2 and Bax in all of U87,
U251, and SHG44 cells after BNCT treatment in efforts
to understand the impact of BNCT on the mitochon-
drial pathway of apoptosis. Down-regulation of Bcl-2
and up-regulation of Bax synthesis after BNCT showed
that apoptosis induced by BNCT may be mediated
through the mitochondrial pathway.
A Bcl-2 antisense has been developed as a gene thera-
peutic agent to treat cancer, such as: melanoma carci-
noma, multiple myeloma, and small cell lung cancer [28].
Elimination of Bcl-2 induced by BNCT indicates that a
directed Bcl-2-targeting strategy may be combined with
BNCT, thus possibly leading to synergistic reduction of
Bcl-2; this possibility deserves further investigation.
Our investigation of BPA-BNCT therapy was con-
ducted in vitro, and many constraints are involved in
attempts to extrapolate in vitro data to the in vivo con-
text. During BNCT, the normal brain tissue and tumors
are non-specifically irradiated by reactor-generated
mixed irradiation beam components, and the patient
tolerance to BNCT could be impaired. When it is con-
sidered that the RBE of BNCT is higher than that of g-
rays, neutron beam, and X-rays, all of which are widely
used as treatment options for patients with brain
tumors, the absorbed dose from BNCT can be much
lower than those strategies. This will limit irradiation
damage to normal tissue. The boron level in blood and
brain parenchyma also contributes to the irradiation
dose to normal tissue. With the development of boron
containing agents and the optimization of strategies of
delivery, [
10B] can be highly accumulated in tumor cells
and the level in normal cells becomes relatively lower
[2,13,35,36]. Moreover, BNCT relies mainly on the use
of boron compounds, and not on a neutron beam per
se, to selectively irradiate a tumor [37]. Thus, the opti-
mization of selective boron delivery to tumor cells is an
important area of BNCT research. As known the BBB
can impede the uptake of boron-containing compounds
by tumor cells, with the invasive properties of glioma
tumors, the BBB can be destroyed and the boron uptake
by tumor cells could be increased. Drugs such as manni-
tol that transiently compromise BBB integrity have been
used to improve boron absorbance by tumor cells. Over-
all, the use of BNCT in vivo will likely become effective,
with a reduction in side effects and improvements in
tumor-targeting boron compounds, following further
development.
Conclusions
Altogether, induction of apoptosis contributes to the
main therapeutic efficacy of BNCT to glioma cells in
vitro. Activation of Bax and downregulation of Bcl-2 are
involvement in the apoptosis triggered by BNCT. More-
over, the RBE of BPA-BNCT is higher than that of g-ray
and reactor neutron irradiation. Understanding the
mechanisms involved in BNCT will ultimately contri-
bute to the enhancement of the therapeutic effectiveness
of this therapeutic modality.
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